MENS logo

JYONG BIOTECH LTD

MENSNASDAQ
🏆 #3884 by market capUS Equity
$2.00▼ $0.03 (−1.48%)
Live
🔔
Track MENS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.5%
7d▼ 6.3%
14d▼ 5.9%
30d▼ 13.4%
ytd▼ 50.0%
1y▼ 95.3%
🏦Market Cap
$152M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
—
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$1.98 – $2.02
52-Week Range
$1.43 – $63.00
Volume
$2.71B
Avg Volume
$3.41B
Shares Outstanding
76.0M
Next Earnings
Oct 20, 2026

Fundamentals Snapshot

Annual Revenue
$40M
Last Q Revenue
$9M
P/E Ratio
-22.8
P/S Ratio
0.0x
EPS (TTM)
$-0.06
Dividend Yield
0.00%
Dilution (1yr)
+103626.1%

Why Investors Own MENS

  • ✓High-growth profile — revenue up +37.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 33% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MENS logo

JYONG BIOTECH LTD

MENS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$3M▲ +26.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$3M▼ −16.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
74.2M▲ +103626.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$17M▲ +$666K YoY
StockOtter · stockotter.space

About JYONG BIOTECH LTD

Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$2.67
▲ +33.4% Upside
High Target$2.95
Low Target$2.22
Based on 38 analysts

Latest News & Updates

GlobeNewsWire·27d ago

Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow

New Taipei City, Taiwan/San Francisco, CA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd.

Globe News Wire·Jul 23

Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships

New Taipei City, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization o

GlobeNewsWire·Jul 2

Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention

New Taipei City, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization o